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Imbalance of p75NTR/TrkB protein expression in
Huntington’s disease: implication for neuroprotective
therapies
V Brito1,2,3, M Puigdellı´vol1,2,3, A Giralt1,2,3, D del Toro4, J Alberch1,2,3 and S Gine´s*,1,2,3
Neuroprotective therapies based on brain-derived neurotrophic factor (BDNF) administration have been proposed for
Huntington’s disease (HD) treatment. However, our group has recently reported reduced levels of TrkB in HD mouse models and
HD human brain suggesting that besides a decrease on BDNF levels a reduction of TrkB expression could also contribute to
diminished neurotrophic support in HD. BDNF can also bind to p75 neurotrophin receptor (p75NTR) modulating TrkB signaling.
Therefore, in this study we have analyzed the levels of p75NTR in several HD models, as well as in HD human brain. Our data
demonstrates a p75NTR/TrkB imbalance in the striatum of two different HD mouse models, HdhQ111/111 homozygous knockin mice
and R6/1 mice that was also manifested in the putamen of HD patients. The imbalance between TrkB and p75NTR levels in a HD
cellular model did not affect BDNF-mediated TrkB activation of prosurvival pathways but induced activation of apoptotic
cascades as demonstrated by increased JNK phosphorylation. Moreover, BDNF failed to protect mutant huntingtin striatal cells
transfected with p75NTR against NMDA-mediated excitotoxicity, which was associated with decreased Akt phosphorylation.
Interestingly, lack of Akt activation following BDNF and NMDA treatment correlated with increased PP1 levels. Accordingly,
pharmacological inhibition of PP1 by okadaic acid (OA) prevented mutant huntingtin striatal cell death induced by NMDA and
BDNF. Altogether, our findings demonstrate that the p75NTR/TrkB imbalance induced by mutant huntingtin in striatal cells
associated with the aberrant activity of PP1 disturbs BDNF neuroprotection likely contributing to increasing striatal vulnerability
in HD. On the basis of this data we hypothesize that normalization of p75NTR and/or TrkB expression or their signaling will
improve BDNF neuroprotective therapies in HD.
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Deficits of neurotrophic support caused by reduced levels of
brain-derived neurotrophic factor (BDNF) have been impli-
cated in the selective vulnerability of striatal neurons in
Huntington’s disease (HD).1 Neuroprotective therapies based
on BDNF administration have been proposed to slow or
prevent the HD disease progression. However, the effective-
ness of BDNF may depend on the proper expression of its
neuronal receptor TrkB. Indeed, reduced striatal TrkB
expression has been reported in knockin HD cellular and
mouse models, exon-1 HD transgenic mice and HD human
brain,2–4 which suggests that mutant huntingtin could lead to
reduced neurotrophic support not only by altering BDNF levels
but also by affecting TrkB expression. This scenario can still
be more complex as BDNF also binds to p75NTR a member of
the tumor necrosis factor receptor superfamily.5 In contrast to
Trk receptors, which have a well-defined trophic role, p75NTR
may promote a variety of complex and sometimes opposing
functions ranging from trophism to apoptosis depending on
the cellular context and coexpression with Trk receptors.6,7
Thus, p75NTR can either potentiate or reduce neurotrophic Trk
receptor function or act independently to induce apoptotic
signaling cascades.5,8,9 In the adult brain, p75NTR expression
is downregulated in most brain areas.10,11 However, in
damaged or diseased conditions p75NTR expression is rapidly
induced, which has been associated with neuronal cell
death.7,12 Thus, in neonatal mice brain, NMDA-induced injury
is associated with upregulation of p75NTR13,14 while in rats
excitotoxicity induced by kainate administration causes an
increase on p75NTR levels accompanied by a significant cell
death.15 Importantly, in HD, striatal neurons are selectively
vulnerable to glutamate-induced neurotoxicity suggesting that
excitotoxicity has an important role in HD striatal neurode-
generation.16 In this view, Zuccato et al. have demonstrated
increased p75NTR but reduced TrkB mRNA expression in the
caudate but not in the cortex of HD patients4 while impaired
TrkB-mediated ERK1/2 activation was recently reported by
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our group in HD striatal cell lines.3 Altogether, this data
suggest that neurotrophic deficits in HD could account not
only for BDNF reduction but also for an imbalance between
TrkB and p75NTR-mediated cell signaling. To test this
hypothesis we have analyzed the levels of p75NTR and TrkB
in the striatum of two distinct HD mouse models at different
HD pathological stages, as well as in the putamen of HD
patients. We found an imbalance between p75NTR and TrkB
levels that was associated with a reduction of BDNF-mediated
neuroprotection against NMDA excitotoxicity. Altogether, our
findings support the idea that normalization of TrkB and
p75NTR protein levels or their functional signaling cross-talk
would be a major step to improve neuroprotective therapies
with BDNF in HD.
Results
p75NTR and TrkB protein levels are altered in the striatum
of R6/1 mice. Reduced BDNF neuroprotection contributes
to striatal vulnerability in HD.17 Given that BDNF effects can
be mediated by TrkB and p75NTR we analyzed the expres-
sion of these receptors in the striatum of wild-type and
mutant huntingtin R6/1 mice at different HD pathological
stages (Figure 1a). p75NTR protein levels were significantly
increased in the striatum of R6/1 mice at 12 weeks of age
(B50%) an increase that was even more evident at 30 weeks
(B120%) revealing an effect of age and genotype on
changes in p75NTR (F(3,18)¼ 4.133; Po0.05). By contrast, a
significant reduction of TrkB was found in R6/1 only at late
disease stages (B40%). As we described that reduced TrkB
was associated with decreased TrkB transcription2 we
examined whether increased p75NTR mRNA expression
could account for upregulation of p75NTR protein levels. A
significant increase in p75NTR mRNA was found in the
striatum of R6/1 mice at 30 weeks of age (WT:1.0±0.3 and
R6/1:2.3±0.4, Po0.05) indicating that both p75NTR mRNA
and protein are increased in R6/1 mice. To further evaluate
the expression and distribution of p75NTR immunohistochem-
istry analysis was performed in striatal slices from wild-type
and R6/1 mice at 30 weeks of age (Figure 1b). According to
the biochemical data a significant increase (B30%) on
p75NTR staining was revealed in mutant compared with wild-
type mice. As striatal neuronal loss has a characteristic
rostro-caudal gradient of pathological damage,18 p75NTR
levels were analyzed on coronal sections across the rostro-
caudal extension of the striatum (Figure 1c). Significant
Figure 1 Imbalance between p75NTR and TrkB expression in the striatum of R6/1 mice. (a) Representative immunoblots showing the levels of p75NTR, TrkB and b-actin as
a loading control in striatal extracts obtained from WT and R6/1 mice at 8 and 30 weeks of age. The histograms represent the relative levels of p75NTR and TrkB expressed as
percentage of wild-type values. Values are given as mean±S.E.M. of 5–6 independent samples. Data was analyzed by two-way ANOVA followed by Student’s t-test.
*Po0.05; **Po0.01; ***Po0.001 respect to wild-type mice. (b) Representative immunohistochemical images depicting levels of p75NTR staining in the striatum of WT and
R6/1 mice at 30 weeks of age. The histogram represents the mean fluorescence intensity of p75NTR (mean±S.E.M., n¼ 3) expressed as percentage of wild-type levels. Data
was analyzed by Student’s t-test **Po0.01 respect to wild-type mice. Scale bar, 10 mm. (c) The histogram represents the mean fluorescence intensity of p75NTR staining
along rostral to caudal striatal sections from WT and R6/1 mice at 30 weeks of age expressed as percentage of wild-type values (mean±S.E.M. n¼ 3). Data was analyzed by
Student’s t-test *Po0.05; **Po0.01 respect to wild-type mice
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Figure 2 p75NTR and TrkB protein levels are also modified in the striatum of full-length HdhQ111/111 mutant mice. (a) Representative immunoblots showing the levels of
p75NTR, TrkB and b-actin as a loading control in striatal extracts obtained from wild-type HdhQ7/7 and mutant HdhQ111/111 mice at 1, 2 and 12 months of age. The histograms
represent the relative levels of p75NTR and TrkB expressed as percentage of wild-type values. Values are given as mean±S.E.M. of 5–6 independent samples. Data was
analyzed by two-way ANOVA followed by Student’s t-test. *Po0.05; **Po0.01; ***Po0.001 respect to wild-type mice. (b) (Upper panel) double immunostaining showing
p75NTR and DARPP32 in the striatum of wild-type (HdhQ7/7) and mutant (HdhQ111/Q111) mice at 12 months of age. Some cells are single-labeled for p75NTR (arrows), whereas a
high proportion of cells are double-labeled for p75NTR and DARPP32 in both wild-type and HD mutant mice (arrowheads). (Middle panel) double immunostaining showing
p75NTR and parvalbumine staining in the striatum of mutant HdhQ111/111 mice at 12 months of age. Most of the parvalbumine-positive neurons are also positive for p75NTR.
(Bottom panel) Double immunostaining showing p75NTR and GFAP in the striatum of mutant (HdhQ111/111) mice at 12 months of age. p75NTR and GFAP immunoreactivity
demonstrates lack of colocalization. Scale Bar, 25 mm
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Figure 3 The putamen of HD patients shows altered p75NTR and TrkB protein levels. (a) Human brain tissue from 10 control and 9 HD cases were analyzed by western
blot. Immunoblots were probed with p75NTR, TrkB, b-actin as loading control and NeuN and GFAP as neuronal and astroglial markers, respectively. Scatter plots display the
relative levels of p75NTR and TrkB normalized to actin, NeuN or GFAP. The horizontal line represents the normalized mean value in control and HD subjects. Data was
analyzed using Student’s t-test. **Po0.01, ***Po0.001 compared with control. (b) Immunohistochemistry in caudate-putamen of HD brain (Vonsatel grade 1) showing
extensive colocalization between DARPP32 (striatal neuronal marker) and p75NTR. Nuclear staining was revealed by DAPI labeling to show that glia cells (arrows) are not
positive for p75NTR in contrast to neuronal cells (arrowheads). Scale bar, 10 mm
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differences were detected along the rostro-caudal striatum
with the rostral sections having significantly more p75NTR
staining, which suggest a correlation between p75NTR levels
and striatal atrophy.
Knockin HdhQ111/111 mutant mice also display p75NTR/
TrkB imbalance in the striatum. We next analyzed
whether in a different HD mouse model expressing endo-
genous levels of full-length mutant huntingtin (HdhQ111/111)
the expression of both receptors was also altered. No
significant differences on p75NTR levels between wild-type
and mutant mice were found at 1 month of age while a
significant increase was evident at 2 months
(B80%), 5 and 8 months (B90%) and 12 months of age
(B135%) (Figure 2a). Similar to that observed in R6/1 mice
the increase on p75NTR was (1) progressive, starting at 2
months of age and worsening thereafter (F(4,32)¼ 7,415;
Po0.001) and (2) associated with upregulation of p75NTR
mRNA expression (HdhQ7/7:1.0±0.1 and HdhQ111/
111:1.8±0.3, Po0.05). When TrkB levels were examined
we found a significant decrease (B40%) at early HD stages
that was sustained along the disease progression
(Figure 2a). Given that p75NTR can be upregulated by
neurons or glia19 double immunostaining for p75NTR,
DARPP32 and parvalbumin as GABAergic striatal neuronal
markers and GFAP as astroglial marker was performed
(Figure 2b). Confocal analysis revealed that the majority of
DARPP32-positive cells were also positive for p75NTR
indicating a neuronal distribution of p75NTR. We
also observed p75NTR-positive cells that were negative for
DARPP32 that could correspond to parvalbumin interneur-
ons. Double immunolabeling confirm colocalization between
p75NTR and parvalbumin indicating that p75NTR was also
localized in these GABAergic interneurons. Importantly,
p75NTR immunoreactivity failed to colocalize with GFAP
demonstrating that p75NTR was not detectable in astrocytes.
Changes on p75NTR and TrkB protein levels are mani-
fested in the putamen of HD patients. Next we analyzed
whether aberrant p75NTR and TrkB protein levels were
recapitulated in HD human brain. Upon normalization to
actin we found in HD samples a significant increase in
p75NTR (B100%) together with a decrease in TrkB (B60%)
levels compared with control samples (Figure 3a). The levels
of p75NTR were also normalized to NeuN and GFAP.
Normalization to GFAP yielded no significant changes
compared with control samples while a significant increase
was found when normalized to NeuN (B300%). To further
Figure 4 BDNF induces proapoptotic signaling cascades in corticostriatal slices
from mutant HdhQ111/Q111 mice. Seven-month-old wild-type (HdhQ7/7) and mutant
(HdhQ111/111) mice were injected with GFP-AAV scramble shRNA (scramble shRNA)
or GFP-AAV-p75shRNA (p75shRNA) and corticostriatal slices obtained 1 month later.
Slices were incubated with BDNF (200 ng/ml) and cell survival determined by a CKK8
assay 24 h later. (a) (Left) Representative immunoblots showing the levels of p75NTR
and a-tubulin as a loading control in extracts obtained from corticostriatal slices
obtained from wild-type HdhQ7/7 and mutant HdhQ111/111 mice injected with AAV
expressing scramble shRNA or p75 shRNA. The histogram represents the relative
levels of p75NTR expressed as percentage of wild-type values. Values are given as
mean±S.E.M. of four slices/condition/experiment (n¼ 3). Data was analyzed by
Student’s t-test *Po0.05 respect to wild-type mice. (Right) Confocal microscopy of
corticostriatal slices transduced with AAV expressing p75shRNA or scramble shRNA
and labeled for p75NTR expression (red). Transduction of p75shRNA results in lack of
p75NTR expression as indicated by the absence of red p75NTR labeling in GFP-positive
cells. (b) Histograms showing the quantification of cell survival expressed as the
percentage of scramble shRNA transduced cells (control). Values are given as
mean±S.E.M. of four slices/condition/experiment (n¼ 3). Data was analyzed by
one-way ANOVA followed by Turkey’s Multiple comparison test or Student’s t-test
*Po0.05; **Po0.01 respect to wild-type mice, þPo0.05 respect to scramble
shRNAþBDNF treatment. (c) Representative immunoblots showing the levels of
JNK, p-JNK and a-tubulin as a loading control in extracts obtained from corticostriatal
slices obtained from wild-type HdhQ7/7 and mutant HdhQ111/111 mice and incubated
with BDNF for 24 h. The histograms represent the relative p-JNK/JNK ratios
considering 100% the ratio obtained in scramble shRNA conditions (control). Values
are given as mean±S.E.M. of three independent experiments. Data was analyzed by
Student’s t-test *Po0.05 respect to wild-type mice, þPo0.05 respect to scramble
shRNAþBDNF treatment
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confirm the neuronal distribution of p75NTR in HD human
brain double immunolabeling for p75NTR and DARPP32 was
performed in HD caudate-putamen brain sections. Confocal
analysis demonstrated colocalization of p75NTR and
DARPP32 revealing that p75NTR is primary neuronal in HD
human brain, which agrees with our immunohistochemistry
data in knockin HD mutant mice. Consistently, glia cells
indentified by DAPI staining as cells with bright and
condensed nuclei were negative for p75NTR immunostaining.
BDNF treatment reduces the cell survival of cortico-
striatal slices from knockin HdhQ111/111 mutant mice.
Given the importance of TrkB to mediate BDNF neuroprotec-
tion we analyzed whether the p75NTR/TrkB imbalance in HD
might influence BDNF-induced cell survival. To this aim
adeno-associated viruses (AAV) expressing p75 shRNA or
scramble shRNA were bilaterally injected into the striatum of
wild-type and HD mice, corticostriatal slices obtained and cell
survival analyzed following BDNF treatment (Figure 4). First,
we examined viability of tissue slices by fluorescence
microscopy using calcein as a vital dye and propidium iodide
as a marker for cell death. An optimal preservation of slices
as judged from the cell viability achieved was found
(Supplementary Figure S1a). Then we analyzed the efficiency
of AAV-p75shRNA to knockdown p75NTR. Western blot
analysis demonstrated a significant reduction of p75NTR in
wild-type and mutant corticostriatal slices (B50% and 40%,
respectively; Po0.05). Histological analysis by confocal
microscopy further confirmed lack of p75NTR expression in
neurons transduced with p75shRNA (Figure 4a). Finally, cell
survival was evaluated in BDNF-treated slices (Figure 4b).
BDNF incubation increased the cell survival of wild-type
corticostriatal slices (B40%) while a significant reduction was
found in HD slices (B30%) suggesting that p75NTR/TrkB
imbalance negatively modulates BDNF neuroprotection.
Interestingly, reduction of p75NTR levels in the striatum of
wild-type mice increased the survival of corticostriatal slices
(B50%) while in HD mice not only increased the cell
survival but also prevented the cell death induced by
BDNF (Figure 4b). Because JNK activation mediates the
proapoptotic actions of neurotrophins20,21 we next determined
whether the cell death induced by BDNF was associated
with increased JNK phosphorylation. A significant
increase (B20%) in p-JNK levels was found in extracts
obtained from mutant corticostriatal slices treated with
BDNF suggesting a correlation between levels of p-JNK
and cell death (Figure 4c). Consistent with this idea
reduction of p75NTR in wild-type and HD mice significantly
decreased JNK phosphorylation (B25% andB15%, respec-
tively, Figure 4c).
Reduced cell survival of GFP-p75-transfected STHdh111/
111Q mutant cells after BDNF treatment is associated
with activation of JNK pathway. To further analyze the
role of p75NTR/TrkB imbalance in BDNF striatal neuroprotec-
tion immortalized striatal cell lines that express wild-type
(STHdh7/7Q) or mutant full-length huntingtin (STHdh111/111Q)
were used. These mutant cells exhibit reduced levels of
TrkB3 but lack p75NTR expression (Supplementary Figure
S2b). Therefore, to mimic the p75NTR/TrkB imbalance
observed in HD mutant mice, STHdh7/7Q and STHdh111/
111Q cells were transfected with GFP or GFP-p75NTR
(Supplementary Figure S2b) and then incubated with BDNF.
BDNF treatment induced a reduction of cell survival (B20%)
in GFP-p75 STHdh111/111Q cells but not in GFP-p75 STHdh7/
7Q cells (Figure 5a) consistent with our data in HD
corticostriatal slices. Next, we analyzed whether the reduc-
tion on cell survival was also related with increased JNK
phosphorylation. A significant increase in p-JNK levels
(B20%) without changes in total JNK were found in
STHdh111/111Q cells expressing GFP-p75 but not GFP
(Figure 5b). Then we analyzed whether BDNF-mediated
activation of Akt and ERK1/2 pathways was preserved in
STHdh7/7Q and STHdh111/111Q cells transfected with GFP-
p75. It is important to mention that STHdh111/111Q cells
exhibit increased p-Akt and decreased p-ERK levels at basal
conditions,3,22 levels that were not altered by overexpression
of p75NTR (Supplementary Figure S2c). Western blot
analysis revealed that BDNF treatment induced a significant
increase in Akt phosphorylation in both
STHdh7/7Q and STHdh111/111Q cells transfected with GFP
(B100%) and GFP-p75 (B200%) (Figure 5c). Interestingly,
the increase on Akt phosphorylation was significantly higher
in GFP-p75-transfected cells than in GFP cells suggesting
that overexpression of p75NTR facilitates TrkB-mediated Akt
activation. When ERK1/2 phosphorylation was analyzed we
found that BDNF treatment induced a robust and similar
activation (B140%) of p-ERK1/2 in GFP and GFP-p75
STHdh7/7Q cells (Figure 5c). In contrast, ERK1/2 phosphor-
ylation was not increased in BDNF-treated GFP or GFP-p75
STHdh111/111Q cells, which agrees with our own published
data showing impaired TrkB-mediated ERK1/2 activation in
mutant cells.3 These findings indicate that altered p75NTR/
TrkB expression modifies BDNF-mediated neuroprotection
by increasing the activation of the proapoptotic pathway JNK.
BDNF fails to protect GFP-p75-transfected STHdh111/111Q
mutant cells against NMDA-induced excitotoxicity.
BDNF-mediated TrkB signaling is required to protect striatal
neurons against NMDA-induced excitotoxicity,23 which is well
known to contributes to the striatal cell loss in HD.16
Therefore, we investigated whether the p75NTR/TrkB imbal-
ance could affect BDNF neuroprotection against NMDA.
GFP or GFP-p75 transfected STHdh7/7Q and STHdh111/111Q
cells were treated with BDNF before NMDA exposure and
cell survival was analyzed 24 h later (Figure 6). NMDA
treatment induced a significant reduction of cell survival in
both STHdh7/7Q (B30%) and STHdh111/111Q cells (B50%)
(Figure 6a). Addition of BDNF before NMDA completely
prevented NMDA-induced cell death in STHdh7/7Q cells
independently of p75NTR expression (Figure 6a). Surpris-
ingly, in GFP-p75 STHdh111/111Q cells BDNF treatment not
only failed to protect striatal cells against NMDA-induced cell
death but also potentiated it (B20%). As activation of
caspase-3 following NMDA treatment was described in this
mutant huntingtin cell line24 we evaluated whether caspase-3
activation was involved in the lack of BDNF neuroprotection
against NMDA (Figure 6b). Similar caspase-3 activation
was found in GFP or GFP-p75 mutant cells following
NMDA incubation (B40%). However, we found that BDNF
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Figure 5 BDNF-mediated reduction of the survival of GFP-p75 STHdh111/111Q mutant cells is associated with activation of apoptotic pathways. Wild-type (ST7/7Q) and mutant
(ST111/111Q) huntingtin striatal cells transfected with GFP or GFP-p75 were treated with BDNF (50 ng/ml, 30 min) and cell survival was evaluated 24 h later by scoring the percentage
of Hoechst-stained nuclei. (a) Photomicrographs of ST7/7Q and ST111/111Q cells stained with Hoechst showing a significant reduction of cell survival in BDNF-treated GFP-p75
ST111/111Q cells. Scale bar, 10mm. Quantification of surviving cells is shown as the percentage of total cells in control conditions. The results are representative of seven independent
experiments performed in triplicate and are expressed as the mean±S.E.M. Data was analyzed by one-way ANOVA followed by Student’s t-test *Po0.05 versus vehicle-treated
GFP-p75 mutant cells. (b) Representative immunoblot showing the levels of JNK, p-JNK and a-tubulin as a loading control in striatal extracts obtained from mutant ST111/111Q cells
incubated with BDNF (50 ng/ml, 3 h). The histogram represents the relative p-JNK/JNK ratio considering 100% the ratio obtained in control conditions (vehicle). Values are given as
mean±S.E.M. Data was analyzed by Student’s t-test. ***Po0.001 versus vehicle-treated GFP-p75 cells. (c) Representative immunoblots showing the levels of Ser-473-Akt (p-Akt),
Akt, phosphoERK1/2 (p-ERK1/2), ERK1/2 and a-tubulin as a loading control in striatal extracts obtained from wild-type (ST7/7Q) and mutant (ST111/111Q) cells transfected with GFP
or GFP-p75 and treated with BDNF (50 ng/ml) for the indicated time points. Blots are representative of four independent experiments. The histograms represent the relative p-Akt/Akt
and p-ERK/ERK ratios considering 100% the ratio obtained in control condition (vehicle). Values are given as mean±S.E.M. Data was analyzed by Student’s t-test. þPo0.05,
þ þPo0.01 versus vehicle-treated GFP cells, *Po0.05, **Po0.01,***Po0.001 versus vehicle-treated GFP-p75 cells, $Po0.05 versus BDNF-treated GFP cells
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completely blocked NMDA-induced activation of caspase-3
in GFP mutant cells while a significant increase (B75%) was
still observed in GFP-p75 mutant cells consistent with the
lack of BDNF neuroprotection against NMDA.
Lack of BDNF neuroprotection against NMDA correlates
with decreased Akt phosphorylation in GFP-p75
STHdh111/111Q mutant cells. As BDNF did not protect
GFP-p75 STHdh111/111Q cells against NMDA we analyzed
activation of Akt and ERK1/2 following BDNF and NMDA
treatment. GFP and GFP-p75 transfected STHdh7/7Q and
STHdh111/111Q cells were incubated with NMDA alone or
with BDNF before NMDA and Akt and ERK1/2 phosphoryla-
tion analyzed by western blot (Figure 7a). NMDA
treatment induced a significant increase in p-Akt levels in
both STHdh7/7Q (GFP: B80% and GFP-p75:B150%) and
STHdh111/111Q cells (B100%) independently of p75NTR
transfection. We then analyzed whether BDNF treatment
could modify this NMDA-induced Akt phosphorylation. We
found that BDNF prevented NMDA-mediated Akt phosphor-
ylation in STHdh7/7Q cells (GFP or GFP-p75) suggesting that
BDNF desensitize wild-type cells to further Akt activation by
Figure 6 BDNF fails to protect GFP-p75 STHdh111/111Q mutant cells against NMDA excitotoxicity. Wild-type (ST7/7Q) and mutant (ST111/111Q) huntingtin striatal cells
transfected with GFP or GFP-p75 were treated with BDNF (50 ng/ml, 30 min), NMDA (500mM, 30 min) or BDNF before addition of NMDA (NMDAþ BDNF) and cell survival
was evaluated 24 h later by scoring the percentage of Hoechst-stained nuclei. (a) Representative photomicrographs of wild-type and mutant huntingtin striatal cells stained
with Hoechst showing the number of surviving cells in the different conditions (Control, NMDA, NMDAþ BDNF and BDNF) Scale bar, 10 mm. Quantification of surviving cells is
shown as the percentage of total cells in control conditions (vehicle). The results are representative of seven independent experiments performed in triplicate and are
expressed as the mean±S.E.M. Data was analyzed by one-way ANOVA followed by Student’s t-test. þ þ þPo0.001 versus vehicle-treated GFP cells, *Po0.05,
***Po0.001 versus vehicle-treated GFP-p75 cells, #Po0.05 NMDA-treated GFP-p75 cells versus NMDAþ BDNF-treated GFP-p75 cells, $$$Po0.001 NMDAþBDNF-
treated GFP mutant cells versus NMDAþBDNF-treated GFP-p75 mutant cells. (b) Mutant huntingtin cells (ST111/111Q) transfected with GFP or GFP-p75 were treated with
BDNF, NMDA or BDNF before NMDA and cell extracts obtained 3 h later. Immunoblots were performed to detect cleaved caspase-3 (p-17 fragment) and a-tubulin as loading
control. The blot is representative of four independent experiments. The histogram represents the relative p-17 levels considering 100% the value obtained in control
conditions (vehicle). Values are given as mean±S.E.M. Data was analyzed by one-way ANOVA followed by Student’s t-test. þ þ þPo0.001 versus vehicle-treated GFP
mutant cells and **Po0.01, ***Po0.001 versus vehicle-treated GFP-p75 mutant cells
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NMDA. Similar results were found when GFP- STHdh111/111Q
cells were analyzed. However, in GFP-p75 STHdh111/111Q
cells BDNF preincubation not only prevented NMDA-induced
phosphorylation of Akt but also decreased to levels below
those in control mutant cells (B50%, Figure 7a). NMDA
treatment induced a significant increase in p-ERK1/2 levels
in both STHdh7/7Q (B50%) and STHdh111/111Q cells
(B250%). Similar to that observed for Akt, BDNF pretreat-
ment prevented subsequent NMDA-mediated ERK1/2 phos-
phorylation independently of p75NTR transfection. These
results indicate that p75NTR/TrkB imbalance disturbs
BDNF-mediated neuroprotection against NMDA by reducing
Akt phosphorylation.
Reduced Akt phosphorylation in GFP-p75-transfected
STHdh111/111Q mutant cells correlates with increased
PP1 levels. Akt phosphorylation at Ser-473 can be regu-
lated by the activity of PP1 and PHLPP1 phosphates.25–27 As
we observed decreased Akt Ser-473-phosphorylation in
GFP-p75 STHdh111/111Q cells after BDNF and NMDA
treatment, PP1 and PHLPP1 levels were evaluated.
A significant increase in PP1 levels was found in GFP
Figure 7 BDNF prevents NMDA-induced phosphorylation of Akt in GFP-p75 STHdh111/111Q mutant cells. Wild-type (ST7/7Q) and mutant (ST111/111Q) huntingtin striatal
cells transfected with GFP or GFP-p75 were treated with BDNF (50 ng/ml, 30 min), NMDA (500mM, 30 min) or BDNF before addition of NMDA (NMDAþBDNF) for the
indicated time periods. Cells were lysed and immunoblots performed to detect Ser-473-Akt (p-Akt) and Akt (a) or phosphoERK1/2 (p-ERK1/2) and ERK1/2 (b). a-tubulin was
used as a loading control. The blots are representative of four independent experiments. The histograms represent the relative p-Akt/Akt and p-ERK/ERK ratios considering
100% the ratio obtained in control conditions (vehicle). Values are given as mean±S.E.M. Data was analyzed by Student’s t-test. þPo0.05, þ þPo0.01, þ þ þPo0.001
versus vehicle-treated GFP cells, *Po0.05 and ***Po0.001 versus vehicle-treated GFP-p75 cells, $Po0.05, $$$Po0.001 NMDAþBDNF-treated GFP mutant cells versus
NMDAþ BDNF-treated GFP-p75 mutant cells
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(B20%) and GFP-p75 (B30%) STHdh111/111Q cells following
NMDA treatment (Figure 8a). Importantly, in GFP-p75 but
not in GFP mutant cells incubation with BDNF before NMDA
significantly increased PP1 levels (B80% compared with
untreated cells andB50% compared with NMDA-treated
cells). No differences on PHLPP1 levels were found between
GFP and GFP-p75 mutant cells at any analyzed condition
(Supplementary Table 2).
Inhibition of PP1 restores Akt phosphorylation and
BDNF neuroprotection in GFP-p75-transfected
STHdh111/111Q mutant cells. To confirm a functional role
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for PP1 in the lack of BDNF neuroprotection GFP and GFP-
p75-transfected STHdh111/111Q cells were treated with OA to
inhibit PP1 activity and p-Akt levels analyzed by western blot
(Figure 8b). Inhibition of PP1 in GFP-p75 STHdh111/111Q cells
blocked the reduction of Akt phosphorylation induced by
BDNF treatment. Moreover and consistent with a detrimental
role of PP1 on BDNF neuroprotection the cell death of GFP-
p75 STHdh111/111Q cells induced by BDNF and/or NMDA was
completely prevented by pretreatment with OA (Figure 8c).
Altogether, these results support the involvement of PP1 in
the increased p75-mediated vulnerability of mutant huntingtin
striatal cells to NMDA excitotoxicity.
Discussion
Several evidences implicate reduced levels of BDNF in HD
pathology, which has emphasized the study of therapeutic
strategies based on BDNF administration for HD treat-
ment.1,28,29 BDNF-mediated neuronal survival is primarily
associated with activation of TrkB receptors.30,31 However,
BDNF can also binds to p75NTR, which could either potentiate
Trk function9,32–34 or signal independently to activate cell
death cascades.20,35,36 In this study, we found an imbalance
between p75NTR and TrkB expression in two distinct HD
mouse models: HdhQ111/111 mutant knockin mice and R6/1
transgenic mice that was also manifested in the putamen of
HD patients supporting the idea that p75NTR/TrkB imbalance
is relevant to HD pathology. p75NTR upregulation was
associated with increased p75NTR mRNA expression, which
agrees with previous studies showing increased p75NTR and
reduced TrkB mRNA levels in the caudate of HD patients.4
Deregulation of gene transcription has been implicated in HD
pathology. In particular upregulation of the transcription factor
Sp1 has been described in cellular and transgenic models of
HD suggesting that increased Sp1-mediated transcription
could contribute to HD pathology.37 Interestingly, p75NTR
expression is dependent on binding of Sp1 to the p75NTR
proximal promoter,38,39 which allows us to speculate that
aberrant Sp1 activity could underlie the upregulation of
p75NTR mRNA in HD. Our data also demonstrate that
upregulation of p75NTR protein levels in HD brain follows a
rostro-caudal gradient with higher p75NTR expression at the
rostral striatum. Notably, brain tomography studies
demonstrate severe atrophy of the head caudate early in the
disease process along the rostro-caudal axis40 suggesting a
correlation between increased p75NTR levels and striatal
atrophy and dysfunction. Consistent with this hypothesis we
found a good colocalization between p75NTR andDARPP32, a
well known marker for striatal medium spiny neurons, the
most vulnerable neurons in HD. In fact, this is the first time
showing p75NTR expression in DARPP32 neurons as most of
the previous studies reported p75NTR immunoreactivity in
large cholinergic interneurons.11 In this new scenario, it is
important to determine whether the imbalance between
p75NTR and TrkB expression could affect BDNF neuroprotec-
tion. Our studies demonstrate reduced cell survival of
STHdh111/111Q mutant cells and corticostriatal slices from
HdhQ111/111 mutant mice after BDNF treatment supporting the
idea that altered expression of BDNF receptors could
contribute to disturbing BDNF neuronal protection. This result
agrees with previous studies showing BDNF-mediated cell
death of hippocampal neurons expressing high levels of
p75NTR but lacking TrkB or TrkC receptors.20,36 Moreover, we
demonstrate that BDNF-induced cell death was associated
with a significant activation of the JNK pathway that was
reported to have an important role in p75NTR-mediated cell
death.41,42 These findings together with our published data
showing lack of BDNF-mediated activation of ERK1/2 in
mutant huntingtin cells (Figure 6 and Gines et al.3) suggest
that mutant huntingtin induces neuronal cell death not only by
altering p75NTR and TrkB expression but also their down-
stream signaling. In view of this data, we propose that
aberrant BDNF signaling could participate in the increased
susceptibility of mutant huntingtin striatal cells to NMDA
excitotoxicity. In support of this hypothesis we found that
BDNF incubation before NMDA treatment not only fails to
reduce GFP-p75 mutant huntingtin cell death but potentiates
it. In association with increased cell death we found higher
caspase-3 activation, which is known to be crucial for cell
death triggered by over-activation of p75NTR.36,43 Similarly,
reduced p75NTR/TrkB ratio as a consequence of seizure
induction in rats also promotes neuronal cell death that was
associated with increased binding of BDNF to p75NTR.44
Besides increased JNK activation lack of BDNF neuroprotec-
tion against NMDA was also related with reduced Akt
activation. Dephosphorylation of Akt depends on several
Figure 8 Lack of BDNF neuroprotection against NMDA excitotoxicity is mediated by PP1-induced dephosphorylation of Akt in GFP-p75 STHdh111/111Q mutant cells.
Mutant huntingtin (ST111/111Q) striatal cells transfected with GFP or GFP-p75 were incubated with BDNF (50 ng/ml, 30 min), NMDA (500mM, 30 min) or BDNF before NMDA
treatment and cell extracts obtained 15 min later. (a) Representative immunoblot showing the levels of PP1 and a- tubulin as loading control. The blot is representative of five
independent experiments. The histogram represents the relative PP1 levels considering 100% the value obtained in control conditions (vehicle). Values are given as
mean±S.E.M. Data was analyzed by Student’s t-test. þPo0.05 versus vehicle-treated GFP cells, **Po0.01 versus vehicle-treated GFP-p75 cells, ##Po0.01
NMDAþ BDNF-treated GFP-p75 cells versus NMDA-treated GFP-p75 cells, $$Po0.01 NMDAþBDNF-treated GFP cells versus NMDAþBDNF-treated GFP-p75 cells.
(b) Mutant huntingtin striatal cells (ST111/111Q) transfected with GFP or GFP-p75 were treated with the PP1 inhibitor OA (200 nM, 30 min) before incubation with BDNF
(50 ng/ml, 30 min), NMDA (500mM, 30 min) or BDNF and NMDA (NMDAþBDNF). Cell extracts were obtained 15 min later and immunoblots performed to detect Ser-473-Akt
(p-Akt), Akt and a-tubulin as a loading control. The blots are representative of four independent experiments. The histograms represent the relative p-Akt/Akt ratio considering
100% the ratio obtained in control conditions (vehicle). Values are given as mean±S.E.M. Data was analyzed by Student’s t-test. þPo0.05, þ þ þPo0.001 versus
vehicle-treated GFP cells, *Po0.05, ***Po0.001 versus vehicle-treated GFP-p75 cells, $Po0.05 NMDAþBDNF-treated GFP cells versus NMDAþ BDNF-treated
GFP-p75 cells. (c) Mutant huntingtin striatal cells (ST111/111Q) transfected with GFP or GFP-p75 were treated with or without OA (200 nM, 30 min) before incubation with
BDNF (50 ng/ml, 30 min) and then exposed to NMDA (500mM, 30 min). Cell survival was evaluated 24 h later by scoring the percentage of Hoechst-stained nuclei.
Representative photomicrographs of wild-type (ST7/7Q) and mutant (ST111/111Q) huntingtin cells stained with Hoechst showing the number of surviving cells in the different
conditions (Control, NMDA, NMDAþ BDNF and BDNF). Scale bar, 10mm. Quantification of surviving cells is shown as the percentage of total cells in control conditions
(vehicle). The results are representative of seven independent experiments performed in triplicate and are expressed as the mean±S.E.M.
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Ser/Thr phosphatases. PP2-A dephosphorylates Akt at
Thr-308,45 whereas PP1 and PHLPP1 at Ser-473.25,27 No
changes on PHLPP1 levels were found in BDNF/NMDA-
treated GFP-p75 mutant huntingtin cells revealing that this
phosphatase unlikely contributes to Akt inactivation. By
contrast, PP1 levels were significantly increased following
BDNF and NMDA treatment suggesting a mechanistic link
between PP1 and Akt inactivation. Supporting this view,
BDNF/NMDA-induced dephosphorylation of Akt was blocked
by inhibition of PP1 by OA treatment. Moreover, we also
demonstrate that PP1-mediated dephosphorylation of Akt
contributes to mutant huntingtin cell death as inhibition of PP1
prevented BDNF/NMDA-induced cell death of GFP-p75
mutant cells. Interestingly deregulation of PP1 activity in HD
mice has been associated with NMDA-mediated striatal cell
death46 and NMDA-induced cell death of retinal ganglion cells
has been related with PP1-mediated Akt dephosphoryla-
tion.26 Altogether, this data suggest that a dysfunctional
signaling cross-talk between TrkB, p75NTR and NMDAR could
contribute to increase striatal cell vulnerability in HD
(Supplementary Figure 3). These results may have important
consequences for the potential use of BDNF as a therapeutic
agent in HD. Thus, exogenous BDNF administration or
pharmacological treatments that raise BDNF levels only
ameliorate or partially improve morphological phenotypes or
motor and cognitive behavior in different HD mouse
models,47–51 which could be related with the dysfunctional
signaling of TrkB and p75NTR demonstrated in the present
study. In view of these results, a better understanding of the
physiological interactions between p75NTR and TrkB in HD
would improve the design of new neuroprotective therapies for
HD treatment
Materials and Methods
Chemicals and antibodies. BDNF was obtained from Peprotech EC Ltd
(London UK), Okadaic Acid was obtained from Tocris (Minneapolis, MN, USA),
NMDA (N-Methyl-D-aspartic acid) from Sigma-Aldrich (St. Louis, MO, USA) and
Lipofectamine 2000 was from Invitrogen (Carlsbad, CA, USA). Phospho p44/42
ERK1/2 (Thr202/Tyr204), Phospho-Akt (Ser-473), Phospho-SAPK/JNK (Thr183/
Tyr185), total ERK1/2, total Akt and total SAPK/JNK were obtained from Cell
Signaling Technology (Beverly, MA, USA). TrkB polyclonal antibody that
recognizes the full-length TrkB isoform (sc-7268; C-tal epitope) was obtained
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). TrkB monoclonal antibody
that recognizes full-length and truncated TrkB isoforms and anti-DARPP32 was
purchased from BD Bioscience (San Jose, CA, USA). Anti-p75NTR was obtained
from Promega (Madison, WI, USA), anti-PP1 (Protein phosphatase 1); anti-
parvalbumine and anti-a-tubulin were purchased from Sigma-Aldrich. Anti-green
fluorescent protein (GFP) was obtained from Abcam (Cambridge, UK). b-actin
(clone C4) was obtained from MP Biomedicals (Irvine, CA, USA), anti-NeuN was
purchased from Millipore (Billerica, Bedford, MA, USA) and anti-GFAP was from
Dako A/S (Glostrup, Denmark). IgG HRP-conjugated anti-mouse or anti-rabbit
antibodies were purchased from Promega and Cy3 anti-rabbit, Cy2 anti-mouse
secondary antibodies were obtained from Jackson Immunoresearch (West Grove,
PA, USA). Alexa Fluor 488 Goat anti-Rabbit IgG conjugate was from Invitrogen.
Cell cultures. Conditionally immortalized wild-type STHdh7/7Q and mutant
STHdh111/111Q striatal neuronal progenitor cell lines expressing endogenous levels
of normal and mutant full-length huntingtin with 7 and 111 glutamines,
respectively, were generated from wild-type HdhQ7/7 and homozygous
HdhQ111/111 littermate embryos.22 The knockin models represent faithfully the
HD mutation carried by patients as elongated polyglutamine tracts are placed
within the correct context of the murine Hdh gene. Thus, immortalized striatal cells
accurately express normal and mutant huntingtin and do not exhibit amino terminal
inclusions, which allow us to study changes involved in early HD pathogenesis.
Striatal cells were grown at 33 1C in Dulbecco’s modified Eagle’s medium (DMEM;
Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS),
1% streptomycin-penicillin, 2 mM L-glutamine, 1 mM sodium pyruvate and 400mg/
ml G418 (Geneticin; Gibco-BRL, Gaithersburg, MD, USA). Mouse septal neuron 
neuroblastoma hybrid SN56 cells (cell line with negligible TrkB expression) and T48
cells (SN56 cells transfected clone expressing TrkB) were created and kindly
provided by Dr. KYe (Department of Pathology, Emory University School of
Medicine, Atlanta). SN56 cells were maintained at 37 1C in DMEM medium
containing 1 mM pyruvate and 10% FBS and T48 cells stably transfected with rat
TrkB were cultured in the same medium but containing 300mg/ml G418.
Genetic Huntington’s disease mouse models. HdhQ111 knockin mice
expressing mutant huntingtin with 111 glutamine residues were maintained on a
C57BL/6 genetic background.52 HdhQ7/111 heterozygous males and females were
intercrossed to generate age-matched HdhQ111/111 homozygous and HdhQ7/7 wild-
type littermates. R6/1 transgenic mice (B6CBA background) expressing exon-1
mutant huntingtin with 145 glutamines under the HD human promoter and their
wild-type littermates were obtained from Jackson Laboratory (Bar Harbor, ME,
USA).53 The animals were housed with access to food and water ad libitum in a
colony room kept at 19–22 1C and 40–60% humidity, under a 12 : 12 h light/dark
cycle. All procedures were performed in compliance with the European Community
guidelines for the care and use of the laboratory animals (86/609/EEC), and
approved by the local animal care committee of Universitat de Barcelona (404/12)
and Generalitat de Catalunya (DAAM5712).
Postmortem brain tissues. Samples of the putamen nucleus from one
patient with HD grade 1 (73 years, postmortem intervals of 7 h), nine patients with
HD grade 3 and 4 (71, 63, 65, 60, 47, 44, 40, 39, 28 years, postmortem intervals
of 4–15 h) and 10 control cases (77, 74, 71, 68, 65, 64, 60, 59, 56, 39 years,
postmortem intervals of 4–23 h ) were supplied by the Banc de Teixits Neurolo`gics
(Servei Cientı´fico-Te`cnics, Universitat de Barcelona, Barcelona, Spain). The Banc
de Teixits Neurolo`gics was established to provide human postmortem brains to
researchers in Spain taking into due consideration all the ethical guidelines of the
latest Declaration of Helsinki. Informed consent was obtained from all subjects
under study.
Cell transfection. All DNA constructs were transfected using Lipofectamine
2000 as instructed by the manufacturer. Both wild-type STHdh7/7Q and mutant
STHdh111/111Q huntingtin striatal cells were transfected at 50% of confluence with
human p75 neurotrophin receptor tagged with GFP at the C-terminus (generously
provided by Dr. Formaggio, Department of Medicine and Public Health, Section
Pharmacology, University of Verona, Italy). As a control condition cells were
transfected with GFP vector from Clontech (Palo Alto, CA, USA). Transfection
efficiencies were estimated by flow cytometry and are shown in Supplementary
Table 1.
Quantitative RT-PCR. Total RNA was isolated from striatum of HD mutant
and wild-type mice using the Total RNA Isolation Nucleospin RNA II Kit
(Macherey-Nagel, Du¨ren, Germany). Purified RNA (500 ng) was reverse
transcribed using the StrataScript First Strand cDNA Synthesis System
(Stratagene, Santa Clara, CA, USA). The cDNA synthesis was performed at
42 1C for 60 min in a final volume of 20ml according to the manufacturer’s
instructions. The cDNA was then analyzed by quantitative RT-PCR using the
following TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA,
USA): 18S (Hs99999901_s1) and p75 (Mm00446294_m1). RT-PCR was
performed in 25ml of final volume on 96-well plates, in a reaction buffer
containing 12.5 ml TaqMan Gene Expression Assays and 20 ng of cDNA.
Reactions included 40 cycles of a two-step PCR: 95 1C for 30 s and 60 1C for
1 min, after initial denaturation at 95 1C for 10 min. All quantitative-PCR assays
were performed in duplicate and repeated in at least three independent
experiments. To provide negative controls and exclude contamination by genomic
DNA, the RT was omitted in the cDNA synthesis step, and the samples were
subjected to the PCR reaction in the same manner with each TaqMan Gene
Expression Assay. The quantitative-PCR data was quantified using the
comparative quantitation analysis program of MxPro Q-PCRanalysis software
version 3.0 (Stratagene). The CT) value for each reaction, and the relative level of
gene expression for each sample were calculated using the 2DDCT method.54 To
correct for loading differences, the values were normalized according to the level
of expression of the housekeeping gene, 18S, within each sample. Its CT value
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was subtracted from that of the specific genes to obtain a DCT value. Differences
(DDCT) between the DCT values obtained for the control mice (calibrators) and
the DCT values for the R6/1 or the Hdh
Q111/111 mice were determined. The relative
quantitative value was then expressed as 2DDCT, representing the fold change
in gene expression normalized to the endogenous control and relative to the
calibrators.
Drug treatments of striatal cell lines. All drug treatments were
performed 48 h after transfection. To induce NMDA excitotoxicity transfected
wild-type STHdh7/7Q and mutant STHdh111/111Q huntingtin striatal cells were
exposed to 500mM NMDA for 30 min in Locke’s solution (154 mm NaCl, 5.6 mm
KCl, 2.3 mm CaCl2, 3.6 mm NaHCO3, 5 mm HEPES, 5.6 mm glucose and 10 mm
glycine). After NMDA treatment, medium was replaced by fresh DMEM medium
containing 2.5% FBS and cell survival was analyzed 24 h later. To analyze the
neuroprotective role of BDNF against NMDA-mediated excitotoxicity transfected
wild-type and mutant huntingtin striatal cells were treated for 30 min in serum-free
DMEM medium containing 50 ng/ml BDNF before NMDA exposure (500mM,
30 min). After NMDA treatment medium was replaced by fresh DMEM medium
containing 2.5% FBS and cell survival was analyzed 24 h post-treatment. To
analyze basal BDNF signaling, transfected wild-type and mutant huntingtin striatal
cells were placed in DMEM serum-free medium for 3 h and then exposed to BDNF
(50 ng/ml) for different time periods, (0, 5 and 15 min). To study BDNF signaling in
NMDA-treated conditions transfected wild-type and mutant huntingtin striatal cells
were treated with BDNF (50 ng/ml) for 30 min before NMDA incubation (500mM)
and total cell extracts were collected at different time periods (0, 5 and 15 min). To
analyze apoptotic cascades (cleaved caspase-3 and phospho-JNK levels), cells
were treated with BDNF (50 ng/ml, 30 min) or with BDNF before NMDA exposure
(500mM, 30 min) and cell extracts collected 3 h later. Finally, to test the role of
protein phosphotase 1 (PP1) in HD pathology, mutant striatal cells were exposed
to 200 nM of the PP1 inhibitor ,OA (30 min) before BDNF treatment (50 ng/ml,
30 min). After BDNF incubation cells were treated with NMDA (500 mM, 30 min),
medium replaced by fresh DMEM medium and PP1 levels analyzed by western
blot in total extracts obtained 15 min post-treatment. In parallel experiment cells
were fixed with 4% paraformaldehyde and cell survival analyzed 24 h later.
Cell survival. Cell survival of striatal cells was assessed by nuclear DNA
staining with Hoechst 33258. Cells were washed twice with PBS, fixed with 4%
paraformaldehyde in PBS for 10 min, washed twice in PBS, and stained with
Hoechst 33258 (1 mg/ml) for 5 min. Stained cells were then washed twice with
PBS and mounted under glass coverslips with Mowiol. Cell survival is represented
as the proportion of Hoechst-stained nuclei counted in treated cells compared with
the number of control cells (vehicle-treated). Forty fields were counted per
condition and experiment, comprising at least 30–40 cells. Data are given as
mean±S.E.M. of values obtained in seven independent experiments performed in
triplicate.
AAV-mediated shp75 expression vectors. For knockdown p75NTR
expression we designed a siRNA oligomer targeting the mouse p75NTR: Ngfr-1
(50 GACGCATCCAGAGAGCTGA 30). This siRNA was then used to obtain the
corresponding shRNA to clone into a rAAV2/8-GFP adenoviral vector (BamHI site
at 50 and AgeI at the 30). The rAAV2/8 plasmids and infectious AAV viral particles
containing GFP expression cassette with scrambled shRNA (AAV-shRNAGFP) or
p75shRNA (AAV-shp75GFP) were generated by the Unitat de Produccio´ de
Vectors from the Center of Animal Biotechnology and Gene Therapy at the
Universitat Auto`noma de Barcelona.
Intrastriatal injection of adenoviral vectors. Seven-months-old wild-
type HdhQ7/7 and mutant HdhQ111/111 mice (n¼ 4–5) were deeply anesthetized
with pentobarbital (40–60 mg/Kg) and placed in a stereotaxic apparatus for
bilateral intrastriatal injections of rAAV2/8 expressing shp75 or control shRNA
(3ml; 1,53 109 GC ). A small incision was made in the scalp, and the striatum
was marked using the following stereotaxic coordinates to Bergman:
anteroposterior (AP), þ 0.6 mm; mediolateral (ML), þ 2 mm; and 2.7 mm below
the dural surface with the incisor bar at 3 mm above the interaural line. Viral
vector was injected using a 10ml-Hamilton microliter syringe at an infusion rate of
0, 5 ml/min; the needle was left in place for 5 min to ensure complete diffusion of
the viruses and then slowly retracted from the brain. Four weeks after
injections, the mice were killed to obtain corticostriatal organotypic cultures as
mentioned below.
Corticostriatal organotypic cultures. Corticostriatal slice cultures were
prepared by the interface culture method55 slightly modified. In brief, 8-months-old
wild-type HdhQ7/7 and mutant HdhQ111/111 mice were killed by instant decapitation
and their brains were quickly removed and placed in a petri dish containing
dissecting salt medium (MEMp: (50% (vol/vol) MEM, 25 mM HEPES and 2 mM
glutamine without antibiotics) under sterile conditions. After removal of the
meninges the brains were sectioned coronally (400 mm) by using a McIlwain tissue
chopper (Mickle Laboratory, Cambridge, UK). The resulting brain slices were
placed in incubation culture medium (MEMi: 50% (vol/vol) MEM, 25 mM HEPES,
25% (vol/vol) HBSS, 25% (vol/vol) heat-inactivated horse serum, 2 mM glutamine,
1 ml of penicillin/streptomycin solution and 0.044% (vol/vol) NaHCO3). These
slices were then trimmed to include the dorsal one half of the striatum with the
overlying frontoparietal neocortex. From each donor mice an average of seven
corticostriatal cultures were obtained using both hemispheres. The slices were
stored for 1 h at 4 1C before being transferred to 24-well plates contained inserts of
humidified porous membranes (0,4mm Millicell, 12 mm diameter Millipore) in
250ml of culture medium. The cultures were maintained at 37 1C in a 5% CO2/
95% air atmosphere at a relative humidity of 95%. Culture viability was first
determined by subjective judgment of the transparency, color and border
morphology. To validate the method, the viability of our corticostriatal organotypic
slice cultures was analyzed using a standardized protocol for PI uptake. Briefly, 2 h
after transferring the slices to the transwell, 20 ml of 0,1 mM PI was added to the
organotypic culture. This concentration is kept in the medium during the 24 h
period incubation. After 24 h, slices were then incubated (30 min at 37 1C) with
0.01% Calcein AM, a cell-permeant dye used to determine cell viability (Molecular
Probes Inc., Eugene, OR, USA ) and images were analyzed by confocal
microscopy.
CCK-8 cytotoxicity assay. Cell viability of corticostriatal slices was
assessed by WST-8 assay using the Cell Counting Kit-8 (CCK-8, Sigma-Aldrich,
St. Louis, MO, USA), in which colored formazan was formed in viable cells in
response to cellular dehydrogenase activity. Briefly, after BDNF treatment (200 ng/
ml), 25ml of Cell Counting Assay Kit-8 solution was added to each corticostriatal
slice. After 3 h or 24 h of incubation, 100ml of medium from each slice culture was
dispensed in a 96-well plate and absorbance at 450 nm was measured using a
microplate reader. The cell viability was calculated as the ratio between the
absorbance measurements at 3 h and 24 h and the results expressed as the
percentage of viable cells relative to GFP-vehicle-treated slices (control). Each
experiment contained four readings for each experimental condition.
Immunofluorescence. For immunohistochemical analysis, homozygous
mutant HdhQ111/111 and wild-type HdhQ7/7 mice at 8 months of age or wild-type
and R6/1 mice at 30 weeks of age (n¼ 3 for each condition) were deeply
anesthetized and immediately perfused transcardially with saline followed by
4% paraformaldehyde/phosphate buffer. Brains were removed and postfixed
overnight in the same solution, cryoprotected by immersion in 30% sucrose and
then frozen in dry ice-cooled methylbutane. Serial coronal cryostat sections
(30mm) through the whole brain were collected in PBS as free-floating sections.
Sections were rinsed three times in PBS, incubated with NH4Cl 50 mM, and
permeabilized with PBS containing 0.5% Triton X-100. Blocking was performed
with PBS containing 0, 2% BSA and 5% normal goat serum (Pierce
Biotechnology, Rockford, IL, USA) for 2 h at room temperature. The sections
were then washed in PBS and incubated overnight at 4 1C with anti-p75 (1 : 100),
anti-GFAP (1 : 100), anti-DARPP32 (1 : 1000) or anti-parvalbumin (1 : 1250)
antibodies and detected with Cy3 anti-rabbit and Cy2 anti-mouse (1 : 200)
secondary antibodies. Following secondary antibody incubation, slices were rinsed
in PBS. As negative controls, some sections were processed as described in the
absence of primary antibody and no signal was detected. Immunofluorescence
was analyzed by confocal microscopy using a TCS SL laser scanning confocal
spectral microscope (Leica Microsystems Heidelberg GmbH, Manheim, Germany).
For human brain immunofluorescence analysis, paraffin sections of the putamen
nucleus from one patient with HD grade 1 (73 years, 7 h postmortem) was
supplied by the Banc de Teixits Neurolo`gics (Servei Cientı´fico-Te`cnics, Universitat
de Barcelona, Barcelona, Spain). Paraffin sections were dewaxed and rehydrated
using a xylene/ethanol series followed by rinsing with PBS. Heat-induced epitope
retrieval was performed in citrate buffer, pH 6.0 (DAKO) for 20 min. Sections were
rinsed three times in PBS, incubated with NH4Cl 50 mM, and permeabilized with
PBS containing 0.2% Triton X-100 for 45 min. Blocking was performed with PBS
containing 1% BSA and 10% normal horse serum (Pierce) for 1 h at room
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temperature. After washing sections were incubated overnight at 4 1C with anti-
p75 (1 : 100), and anti-DARPP32 (1 : 1000) diluted in blocking buffer and detected
with Alexa Fluor 488 Goat anti-Rabbit IgG Conjugate (green) and Cy2 anti-mouse
(1 : 200) secondary antibodies. Following secondary antibody incubation, slices
were rinsed in PBS. As negative controls, some sections were processed as
described in the absence of primary antibody and no signal was detected.
Immunofluorescence was analyzed by confocal microscopy using a Leica TCS
SP5 laser scanning spectral confocal microscope (Leica) with Argon and HeNe
lasers attached to a Leica DMI6000 inverted microscope.
Image analysis of striatal coronal sections. Coronal sections spaced
240mm apart comprising rostral, middle and caudal levels of the striatum
(1,54 mm to  0.7 mm from Bergman) from wild-type and R6/1 mice (n¼ 3) were
examined with Leica TCS SP5 laser scanning spectral confocal microscope
(Leica) with Argon and HeNe lasers attached to a Leica DMI6000 inverted
microscope. Confocal images were taken using a  40 numerical aperture
objective with a  1 digital zoom and standard (one Airy disk) pinhole. For each
coronal section, the entire three-dimensional stack of images from the ventral
surface to the top of the section was obtained by using the Z drive in the Leica
TCS SP5 microscope. The size of the optical image was 0.5mm. For each sample,
54 sections (6 9) were captured and subsequently stitched using the tile scan
feature of the Leica LAS AF 2.1.1 software to allow complete visualization of the
striatum. Quantitative analyses were performed using the freeware ImageJ v1.33
by Wayne Rasband (National Institutes of Health, Bethesda, MD, USA). Briefly, for
each stitched image maximum projections was generated and mean pixel intensity
was measured from the selected delineated area.
Protein extraction and western blot analysis. Wild-type and HD mice
were killed by cervical dislocation and brains quickly removed, dissected, frozen in
dry ice and stored at  80 1C until use. Protein extracts were prepared from
striatal brain samples and striatal cell cultures by sonication on ice for 10 s in lysis
buffer containing 50 mM Tris base (pH 7.4), 150 mM NaCl, 0.1 mM phenylmethyl-
sulphonyl fluoride, 1% NP-40 and supplemented with 1 mM sodium orthovanadate
and protease inhibitor mixture (Sigma-Aldrich). Samples were centrifuged at
10 000 g for 10 min and the protein contents determined by (Detergent-
Compatible) Protein Assay (Bicinchoninic acid, BCA; Bio-Rad, Hercules, CA,
USA). Protein extracts (30 mg) were mixed with 4X SDS sample buffer, boiled for
5 min, resolved by 8–12% sSDS-polyacrylamide gel electrophoresis and
transferred to nitrocellulose membranes (Schleicher & Schuell, Keene, NH,
USA). Blots were blocked in 10% non-fat powdered milk in Tris-buffered saline
Tween-20 (50 mM Tris-HCl, 150 mM NaCl, pH7.4, 0.05% Tween-20) for 1 h at
room temperature. The membranes were then incubated overnight at 4 1C with
primary antibodies: TrkB polyclonal antibody (1 : 500; cellular extracts), TrkB
monoclonal antibody (1 : 1000, striatal extracts), p75 antibody (1 : 1000), anti-NeuN
(1 : 1000), anti-GFAP (1 : 1000), anti-GFP rabbit antibody (1 : 500), Phospho p44/
42 ERK1/2 (Thr202/Tyr204) (1 : 1000), Phospho-Akt (Ser-473) (1 : 1000),
Phospho-SAPK/JNK (Thr183/Tyr185) (1 : 1000), total ERK1/2 (1 : 2500), total
Akt (1 : 1000), SAPK/JNK (1 : 1000), a-tubulin (1 : 50 000) or b-actin (1 : 20 000).
The membranes were then rinsed three times with Tris-buffered saline Tween-20
(TBS-T) and incubated with horseradish peroxidase-conjugated secondary
antibody for 1 h at room temperature. After washing for 30 min with TBS-T, the
membranes were developed using the enhanced chemiluminescence substrate kit
(Santa Cruz Biotechnology). The Gel-Pro densitometry program (Gel-Pro Analyzer
for Windows- version 4.0.00.001) was used to quantify the different
immunoreactive bands relative to the intensity of the a-tubulin or actin band in
the same membranes. Data are expressed as the mean±S.E.M. of band density
obtained in independent experiments or samples.
Statistical analysis. All of the data were analyzed with the program
GraphPad Prism version 4.0 (GraphPad Software, La Jolla, CA, USA). Results are
expressed as mean±S.E.M. Experimental data were analyzed either by a one- or
two-way ANOVA followed by the post hoc Bonferroni’s multiple comparison test or
by Student’s t-test. A value of Po0.05 was accepted as denoting statistical
significant differences.
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